Chromedx Corp (MNLIF) 0.2210 $MNLIF
ChroMedX Engages Biosensor Development Expert Stephen Cozzette
ACCESSWIRE - Mon Jan 26, 4:03PM CST
TORONTO, ONTARIO / ACCESSWIRE / January 26, 2015 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"
, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Mr. Stephen Cozzette as a consultant on the HemoPalm project focussing on the electrochemical sensor and cartridge development aspects of the project.
ChroMedX Exhibits and Presents at Cantech '15 in Toronto, Canada
ACCESSWIRE - Tue Jan 13, 2:46PM CST
Toronto, Ontario / ACCESSWIRE / January 13, 2015 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company" , a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that the Company will be presenting and exhibiting at the Cantech '15 Technology Conference on Thursday, January 15, 2015 in Toronto, Ontario Canada.
ChroMedX 2014 Progress Update
ACCESSWIRE - Fri Dec 19, 3:19PM CST
Toronto, ON / ACCESSWIRE / December 19, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company" , a developer of in vitro diagnostics and point-of-care technologies is proud to report on the Company's corporate and developmental progress in 2014.
Early Warning News Release of Invidx Corp.
ACCESSWIRE - Mon Dec 15, 9:47AM CST
Toronto, ON / ACCESSWIRE / December 15, 2014 / Invidx Corp. (OTC:MNLIF) (EIY2.F) ("Invidx" , a company controlled by James Samsoondar, the Chief Science Officer and director of the Company, announces that it has acquired ownership and control of 5,474,452 common shares of ChroMedX Corp. (the "Company" or "ChroMedX" through the exercise of an ultrafiltration option by ChroMedX. Prior to this acquisition, Invidx held 15,000,100 common shares of ChroMedX.
Chromedx Completes Acquisition of Automated Ultrafiltration Immunoassay Technology
ACCESSWIRE - Mon Dec 15, 5:37AM CST
Toronto, Ontario / ACCESSWIRE / December 15, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company" , a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the it has closed its previously announced acquisition of patent application PCT/CA2013/050935 related to Automated Ultrafiltration Technology and associated intellectual property ("AUF" from InvidX Corp., pursuant to an option agreement dated June 16, 2014 (the "Option Agreement" . As consideration for the acquisition of the AUF the Company has issued 5,474,452 common shares to InvidX Corp. which was determined based on the 20% discount to the 10-day volume weight average price of the Company's shares immediately preceding the date of exercise of the option as per the terms of the Option Agreement.
ChroMedX Commences AUF Development with Aline Inc. and Spectrum Labs
ACCESSWIRE - Tue Dec 09, 3:37PM CST
TORONTO, ON / ACCESSWIRE / December 9, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company" , a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of ALine Inc. as primary contractor for the development of its recently acquired Automated Ultrafiltration (AUF) Cartridge.
IIROC Trade Resumption - CHX
CNW Group - Mon Dec 01, 7:31AM CST
Trading resumes in:
ChroMedX Acquires Automated Ultrafiltration Immunoassay Technology
ACCESSWIRE - Fri Nov 28, 3:12PM CST
Toronto, ON / ACCESSWIRE / November 28, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company" , a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the acquisition of the Automated Ultrafiltration Technology "AUF" and associated intellectual property.
IIROC Trading Halt - CHX
CNW Group - Fri Nov 28, 12:26PM CST
The following issues have been halted by IIROC:
ChroMedX Announces Biosensor Development and HemoPalm Update
ACCESSWIRE - Mon Nov 24, 2:37AM CST
Toronto, Ontario / ACCESSWIRE / November 24, 2014 / ChroMedX Corp. (the "Company" (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to provide an update on the Company's HemoPalm handheld analyser/Cartridge technology and the commencement of biosensor development.
Chromedx Announces Collaborative Project with McMaster University
ACCESSWIRE - Mon Nov 17, 2:36AM CST
Toronto, Ontario / ACCESSWIRE / November 17, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company" , a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that it has reached an agreement with McMaster University on a collaborative project.
ChroMedX Engages Biosensor Development Expert Stephen Cozzette
ACCESSWIRE - Mon Jan 26, 4:03PM CST
TORONTO, ONTARIO / ACCESSWIRE / January 26, 2015 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"
, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Mr. Stephen Cozzette as a consultant on the HemoPalm project focussing on the electrochemical sensor and cartridge development aspects of the project. ChroMedX Exhibits and Presents at Cantech '15 in Toronto, Canada
ACCESSWIRE - Tue Jan 13, 2:46PM CST
Toronto, Ontario / ACCESSWIRE / January 13, 2015 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"
, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that the Company will be presenting and exhibiting at the Cantech '15 Technology Conference on Thursday, January 15, 2015 in Toronto, Ontario Canada. ChroMedX 2014 Progress Update
ACCESSWIRE - Fri Dec 19, 3:19PM CST
Toronto, ON / ACCESSWIRE / December 19, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"
, a developer of in vitro diagnostics and point-of-care technologies is proud to report on the Company's corporate and developmental progress in 2014. Early Warning News Release of Invidx Corp.
ACCESSWIRE - Mon Dec 15, 9:47AM CST
Toronto, ON / ACCESSWIRE / December 15, 2014 / Invidx Corp. (OTC:MNLIF) (EIY2.F) ("Invidx"
, a company controlled by James Samsoondar, the Chief Science Officer and director of the Company, announces that it has acquired ownership and control of 5,474,452 common shares of ChroMedX Corp. (the "Company" or "ChroMedX" through the exercise of an ultrafiltration option by ChroMedX. Prior to this acquisition, Invidx held 15,000,100 common shares of ChroMedX. Chromedx Completes Acquisition of Automated Ultrafiltration Immunoassay Technology
ACCESSWIRE - Mon Dec 15, 5:37AM CST
Toronto, Ontario / ACCESSWIRE / December 15, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"
, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the it has closed its previously announced acquisition of patent application PCT/CA2013/050935 related to Automated Ultrafiltration Technology and associated intellectual property ("AUF" from InvidX Corp., pursuant to an option agreement dated June 16, 2014 (the "Option Agreement" . As consideration for the acquisition of the AUF the Company has issued 5,474,452 common shares to InvidX Corp. which was determined based on the 20% discount to the 10-day volume weight average price of the Company's shares immediately preceding the date of exercise of the option as per the terms of the Option Agreement. ChroMedX Commences AUF Development with Aline Inc. and Spectrum Labs
ACCESSWIRE - Tue Dec 09, 3:37PM CST
TORONTO, ON / ACCESSWIRE / December 9, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (EIY2.F) (the "Company"
, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of ALine Inc. as primary contractor for the development of its recently acquired Automated Ultrafiltration (AUF) Cartridge. IIROC Trade Resumption - CHX
CNW Group - Mon Dec 01, 7:31AM CST
Trading resumes in:
ChroMedX Acquires Automated Ultrafiltration Immunoassay Technology
ACCESSWIRE - Fri Nov 28, 3:12PM CST
Toronto, ON / ACCESSWIRE / November 28, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"
, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the acquisition of the Automated Ultrafiltration Technology "AUF" and associated intellectual property. IIROC Trading Halt - CHX
CNW Group - Fri Nov 28, 12:26PM CST
The following issues have been halted by IIROC:
ChroMedX Announces Biosensor Development and HemoPalm Update
ACCESSWIRE - Mon Nov 24, 2:37AM CST
Toronto, Ontario / ACCESSWIRE / November 24, 2014 / ChroMedX Corp. (the "Company"
(CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to provide an update on the Company's HemoPalm handheld analyser/Cartridge technology and the commencement of biosensor development. Chromedx Announces Collaborative Project with McMaster University
ACCESSWIRE - Mon Nov 17, 2:36AM CST
Toronto, Ontario / ACCESSWIRE / November 17, 2014 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"
, a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that it has reached an agreement with McMaster University on a collaborative project. 
